Biogen Company Insiders
BIIB Stock | USD 201.99 8.81 4.56% |
About 89 percent of Biogen's insiders are activelly selling. The analysis of the overall insider sentiment regarding Biogen Inc suggests that quite a large number of insiders are panicking. Biogen employs about 7.6 K people. The company is managed by 50 executives with a total tenure of roughly 396 years, averaging almost 7.0 years of service per executive, having 151.4 employees per reported executive.
George Scangos CEO CEO and Director |
Stelios Papadopoulos Chairman Independent Chairman of the Board |
Biogen's Insider Buying Vs Selling
11
Selling | Buying |
Latest Trades
2024-04-02 | Priya Singhal | Disposed 93 @ 213.09 | View | ||
2024-02-22 | Priya Singhal | Disposed 262 @ 221.23 | View | ||
2024-02-16 | Priya Singhal | Disposed 108 @ 221.49 | View | ||
2024-02-15 | Eric K Rowinsky | Acquired 455 @ 222.54 | View | ||
2024-02-12 | Priya Singhal | Disposed 419 @ 239.45 | View | ||
2023-12-11 | Priya Singhal | Disposed 110 @ 248 | View | ||
2023-09-05 | Priya Singhal | Disposed 431 @ 269.43 | View | ||
2023-07-03 | Priya Singhal | Disposed 81 @ 282.87 | View | ||
2023-04-28 | Ginger Gregory | Disposed 2681 @ 300 | View |
Monitoring Biogen's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Biogen |
Biogen's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Biogen's future performance. Based on our forecasts, it is anticipated that Biogen will maintain a workforce of about 7570 employees by May 2024.Biogen's latest congressional trading
Congressional trading in companies like Biogen Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Biogen by those in governmental positions are based on the same information available to the general public.
2023-03-06 | Representative Daniel Goldman | Acquired Under $15K | Verify | ||
2023-01-23 | Representative Shri Thanedar | Acquired $15K to $50K | Verify | ||
2022-08-03 | Representative Kathy Manning | Acquired Under $15K | Verify | ||
2022-03-17 | Representative Josh Gottheimer | Disposed Under $15K | Verify | ||
2021-02-16 | Representative Peter Meijer | Acquired $15K to $50K | Verify | ||
2021-01-04 | Representative Chris Jacobs | Disposed Under $15K | Verify | ||
2020-12-22 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
2019-06-24 | Representative Donna Shalala | Acquired Under $15K | Verify | ||
2019-06-20 | Representative Dean Phillips | Acquired Under $15K | Verify | ||
2019-03-22 | Senator Sheldon Whitehouse | Acquired Under $15K | Verify | ||
2016-07-21 | Senator James M. Inhofe | Acquired $50K to $100K | Verify | ||
2014-07-23 | Senator Susan M Collins | Acquired Under $15K | Verify | ||
2014-07-23 | Senator Susan M. Collins | Acquired Under $15K | Verify |
Biogen Management Team Effectiveness
The company has return on total asset (ROA) of 0.0458 % which means that it generated a profit of $0.0458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0824 %, meaning that it created $0.0824 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.06, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M.The current year's Common Stock Shares Outstanding is expected to grow to about 283 M, whereas Net Income Applicable To Common Shares is forecasted to decline to about 2 B.
Biogen Workforce Comparison
Biogen Inc is number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 8,285. Biogen totals roughly 7,570 in number of employees claiming about 91% of equities under Health Care industry.
Biogen Profit Margins
The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.19 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.19.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.51 | 0.7424 |
|
|
Biogen Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biogen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 0.3333 | 1 | 3 | 240.00 | 450.00 |
2024-03-01 | 0.6765 | 46 | 68 | 139,080 | 78,748 |
2023-12-01 | 0.5 | 3 | 6 | 2,862 | 1,263 |
2023-09-01 | 0.3333 | 3 | 9 | 6,953 | 13,739 |
2023-06-01 | 1.1 | 11 | 10 | 11,226 | 4,362 |
2023-03-01 | 0.5152 | 34 | 66 | 80,501 | 66,488 |
2022-12-01 | 0.6667 | 8 | 12 | 216,273 | 14,720 |
2022-09-01 | 0.4615 | 6 | 13 | 6,582 | 12,893 |
2022-06-01 | 5.5 | 11 | 2 | 14,824 | 323.00 |
2022-03-01 | 0.5143 | 36 | 70 | 133,077 | 106,990 |
2021-12-01 | 0.5 | 4 | 8 | 1,763 | 1,564 |
2021-09-01 | 1.5 | 15 | 10 | 16,056 | 12,481 |
2021-03-01 | 0.5484 | 34 | 62 | 200,073 | 101,781 |
2020-12-01 | 0.375 | 3 | 8 | 3,655 | 3,434 |
2020-09-01 | 0.8 | 4 | 5 | 25,102 | 651.00 |
2020-03-01 | 0.5 | 34 | 68 | 157,453 | 97,036 |
2019-12-01 | 0.25 | 2 | 8 | 627.00 | 2,815 |
2019-09-01 | 0.2222 | 2 | 9 | 375.00 | 2,052 |
2019-06-01 | 2.1111 | 19 | 9 | 141,064 | 7,372 |
2019-03-01 | 0.5538 | 36 | 65 | 235,304 | 102,720 |
2018-12-01 | 0.2857 | 4 | 14 | 1,999 | 4,036 |
2018-09-01 | 0.4 | 2 | 5 | 2,022 | 1,589 |
2018-06-01 | 1.625 | 13 | 8 | 60,441 | 7,564 |
2018-03-01 | 0.6038 | 32 | 53 | 142,851 | 57,041 |
2017-12-01 | 1.0 | 7 | 7 | 41,905 | 1,007 |
2017-09-01 | 1.3333 | 4 | 3 | 7,733 | 12,732 |
2017-06-01 | 1.5455 | 17 | 11 | 91,600 | 20,006 |
2017-03-01 | 0.507 | 36 | 71 | 110,669 | 76,577 |
2016-12-01 | 0.1818 | 2 | 11 | 2,912 | 9,064 |
2016-09-01 | 0.4 | 2 | 5 | 27,570 | 55,207 |
2016-06-01 | 0.9444 | 17 | 18 | 42,414 | 12,683 |
2016-03-01 | 0.4712 | 49 | 104 | 192,450 | 141,920 |
2015-12-01 | 0.4 | 4 | 10 | 312,422 | 7,667 |
2015-06-01 | 0.8333 | 15 | 18 | 14,360 | 21,055 |
2015-03-01 | 0.4468 | 63 | 141 | 266,140 | 310,059 |
2014-12-01 | 0.3333 | 3 | 9 | 21,297 | 10,723 |
2014-09-01 | 0.125 | 1 | 8 | 21,339 | 46,773 |
2014-06-01 | 0.9375 | 15 | 16 | 27,547 | 22,845 |
2014-03-01 | 0.4083 | 49 | 120 | 258,976 | 307,896 |
2013-12-01 | 0.1429 | 2 | 14 | 19,030 | 46,571 |
2013-09-01 | 0.2 | 9 | 45 | 160,974 | 337,546 |
2013-06-01 | 0.3704 | 20 | 54 | 112,087 | 287,983 |
2013-03-01 | 0.5 | 39 | 78 | 269,811 | 255,163 |
2012-12-01 | 0.1111 | 1 | 9 | 5,378 | 24,862 |
2012-09-01 | 0.2941 | 5 | 17 | 89,409 | 189,287 |
2012-06-01 | 0.7188 | 23 | 32 | 146,304 | 301,555 |
2012-03-01 | 0.4857 | 34 | 70 | 256,668 | 247,302 |
2011-12-01 | 0.1538 | 2 | 13 | 2,953 | 18,407 |
2011-09-01 | 0.3929 | 11 | 28 | 114,591 | 264,293 |
2011-06-01 | 0.4324 | 16 | 37 | 105,625 | 204,891 |
2011-03-01 | 0.3671 | 29 | 79 | 266,304 | 178,125 |
2010-12-01 | 0.2105 | 4 | 19 | 56,350 | 128,728 |
2010-09-01 | 0.087 | 2 | 23 | 148,523 | 118,459 |
2010-06-01 | 0.7222 | 13 | 18 | 1,240,164 | 1,247,712 |
2010-03-01 | 0.5 | 20 | 40 | 716,886 | 960,106 |
2009-12-01 | 0.125 | 1 | 8 | 1,000.00 | 154,308 |
2009-06-01 | 2.3333 | 14 | 6 | 132,720 | 6,147 |
2009-03-01 | 0.6071 | 17 | 28 | 381,916 | 112,620 |
2008-12-01 | 0.125 | 1 | 8 | 1,000.00 | 9,218 |
2008-09-01 | 0.7727 | 17 | 22 | 254,361 | 334,911 |
2008-06-01 | 0.0488 | 10 | 205 | 774,250 | 1,525,920 |
2008-03-01 | 0.1264 | 23 | 182 | 600,854 | 167,192 |
2007-12-01 | 0.1538 | 8 | 52 | 147,100 | 232,318 |
2007-09-01 | 0.5 | 23 | 46 | 518,732 | 1,081,470 |
2007-06-01 | 1.25 | 5 | 4 | 15,550 | 8,981 |
2007-03-01 | 0.9394 | 31 | 33 | 808,143 | 289,177 |
2006-12-01 | 0.1951 | 8 | 41 | 526,500 | 1,002,210 |
2006-09-01 | 0.1622 | 6 | 37 | 162,500 | 193,006 |
2006-06-01 | 0.5294 | 9 | 17 | 76,175 | 117,350 |
2006-03-01 | 2.4 | 24 | 10 | 854,400 | 319,500 |
2005-12-01 | 0.12 | 3 | 25 | 98,042 | 195,898 |
2005-09-01 | 0.0364 | 2 | 55 | 20,500 | 126,125 |
2005-06-01 | 0.0345 | 1 | 29 | 20,500 | 41,000 |
2005-03-01 | 0.4182 | 23 | 55 | 1,199,188 | 572,794 |
2004-12-01 | 0.3208 | 34 | 106 | 189,743 | 527,772 |
2004-09-01 | 0.2929 | 29 | 99 | 204,519 | 401,361 |
2004-06-01 | 0.4132 | 50 | 121 | 933,599 | 1,181,091 |
2004-03-01 | 3.6 | 18 | 5 | 736,552 | 32,814 |
2003-12-01 | 2.35 | 47 | 20 | 3,230,135 | 187,458 |
Biogen Notable Stakeholders
A Biogen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biogen often face trade-offs trying to please all of them. Biogen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biogen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Christopher Viehbacher | CEO President | Profile | |
George Scangos | CEO and Director | Profile | |
Stelios Papadopoulos | Independent Chairman of the Board | Profile | |
Robin Kramer | Chief Accounting Officer, Vice President | Profile | |
Paul McKenzie | Executive Vice President - Pharmaceutical Operations & Technology | Profile | |
Alfred Sandrock | Group Senior Vice President Chief Medical Officer | Profile | |
Spyros ArtavanisTsakonas | Senior Vice President Chief Scientific Officer | Profile | |
JeanPaul Kress | Executive Vice President and Presidentident - International and Head of Global Therapeutic Operations | Profile | |
Kenneth Pietro | Executive Vice President - Human Resources | Profile | |
Adam Koppel | Senior Vice President and Chief Strategy Officer | Profile | |
Michael Ehlers | Executive Vice President of Research and Development | Profile | |
Ginger Gregory | Chief Human Resource Officer, Executive Vice President | Profile | |
Daniel Karp | Executive Vice President - Corporate Development | Profile | |
Anirvan Ghosh | Senior Vice President - Research and Early Development | Profile | |
Anabella Villalobos | Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | Profile | |
Matt Griffiths | Senior Vice President CIO | Profile | |
Jeffrey Capello | CFO, Executive Vice President | Profile | |
Michel Vounatsos | Vice President and Chief Commercial Officer | Profile | |
Sanjay Jariwala | Senior Vice President - Worldwide Medical | Profile | |
Mark Hernon | Senior Vice President CIO | Profile | |
Chirfi Guindo | Executive Vice President Head of Global Marketing, Market Access and Customer Innovation | Profile | |
Susan Alexander | Executive Vice President Chief Legal Officer and Corporate Secretary | Profile | |
Catherine Steele | Senior Vice President - Corporate Affairs | Profile | |
Steven Holtzman | Executive Vice President - Corporate Development | Profile | |
Camille Lee | Senior Vice President - Alzheimer's Therapeutic Area | Profile | |
Alisha Alaimo | President America | Profile | |
Michael CPA | Executive CFO | Profile | |
Paul Clancy | CFO and Executive VP of Fin. | Profile | |
Douglas Williams | Executive VP of RandD | Profile | |
Adriana Karaboutis | Executive VP of Technology, Bus. Solutions and Corporate Affairs | Profile | |
John Cox | Executive VP of Pharmaceutical Operations and Technology | Profile | |
Alexander Denner | Independent Director | Profile | |
Eric Rowinsky | Independent Director | Profile | |
William Hawkins | Director | Profile | |
John Chiminski | Director | Profile | |
Caroline Dorsa | Independent Director | Profile | |
Robert Pangia | Independent Director | Profile | |
Jesus Mantas | Director | Profile | |
Richard Mulligan | Independent Director | Profile | |
Stephen Sherwin | Independent Director | Profile | |
Nancy Leaming | Independent Director | Profile | |
Lynn Schenk | Independent Director | Profile | |
Brian Posner | Independent Director | Profile | |
Gregory Covino | Chief Accounting Officer, VP of Fin. and Controller | Profile | |
Natacha Gassenbach | Chief Affairs | Profile | |
Charles Triano | Senior Relations | Profile | |
Adam Keeney | Executive Development | Profile | |
Susan Esq | Executive Officer | Profile | |
Nicole Murphy | Head Technology | Profile | |
Michael Hencke | Head Relations | Profile |
About Biogen Management Performance
The success or failure of an entity such as Biogen Inc often depends on how effective the management is. Biogen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biogen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biogen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.09 | 0.08 | |
Return On Capital Employed | 0.06 | 0.08 | |
Return On Assets | 0.04 | 0.06 | |
Return On Equity | 0.08 | 0.1 |
The data published in Biogen's official financial statements usually reflect Biogen's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Biogen Inc. For example, before you start analyzing numbers published by Biogen accountants, it's critical to develop an understanding of what Biogen's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Biogen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biogen's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Biogen's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biogen Inc. Please utilize our Beneish M Score to check the likelihood of Biogen's management manipulating its earnings.
Biogen Workforce Analysis
Traditionally, organizations such as Biogen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biogen within its industry.Biogen Manpower Efficiency
Return on Biogen Manpower
Revenue Per Employee | 1.3M | |
Revenue Per Executive | 196.7M | |
Net Income Per Employee | 153.4K | |
Net Income Per Executive | 23.2M | |
Working Capital Per Employee | 452.4K | |
Working Capital Per Executive | 68.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Biogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.55) | Earnings Share 7.98 | Revenue Per Share 67.972 | Quarterly Revenue Growth (0.06) | Return On Assets 0.0458 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.